Marlin Equity Partners Acquires Datafarm - Will Be Fully Merged with Liquent

HORSHAM, Pennsylvania, June 1, 2010 - Liquent, Inc. ("Liquent") is pleased to announce that Marlin Equity
Partners ("Marlin") has acquired Datafarm, Inc., a leading provider of
software and services solutions designed to support the regulatory business
processes of life sciences companies. In December 2009, Marlin acquired
Liquent from Thomson Reuters. Datafarm will be fully merged into Liquent.

Shy Kumar, Datafarm's founder and Chief Executive Officer, will join the
Liquent executive team as Senior Vice President and Chief Technology Officer
(CTO) and will report to Rick Riegel, Liquent CEO.

The combined portfolio of software offerings is strengthened with the
addition of Datafarm's S-Cubed, Web Viewer and Desktop Application.
Datafarm's UK and India subsidiaries will also become part of Liquent. In
addition to providing Liquent with additional technical ability and depth,
Liquent's regulatory and clinical outsourcing services capability is
strengthened by more than doubling the number of associates on the team, and
with the addition of Datafarm India provides a proven low-cost, off shore
capability to complement Liquent's current on shore outsourcing services
offerings.

"We are very excited to bring Datafarm and Liquent together into a single
team. As a combined organization, we now have the deepest and broadest
capability to service the industry," commented Rick Riegel. "I am very
excited to have Shy Kumar join our team as well. He is a well-known industry
thought leader and innovator and I look forward to working closely with him
to drive Liquent forward into the future."

"The life sciences industries are converging as they seek to control
costs while accelerating the drug development process world-wide," Shy Kumar
said. "Over the past twelve years, Datafarm's software and services solutions
have been successfully used by hundreds of life sciences companies to
accelerate the regulatory approval process. This merger is consistent with
Datafarm's commitment and strategy to further enhance and expand the
availability of global regulatory submission and outsourcing services
solutions to the life sciences industry. We look forward to combining our
outstanding technology and complementary wealth of experience with Liquent."

"Marlin continues to recognize the life sciences industry's constant
challenge with regulatory change, drive for new product approvals, and
mounting cost pressures. With the acquisition of Datafarm, we are continuing
our investment in Liquent to support their evolving strategy to solve the
industry's complex regulatory challenges," stated Jim Brady, Group President,
Healthcare at Marlin Equity Partners.

About Liquent, Inc. 101 Gibraltar Road, Suite 200 - Horsham, PA 19044
Tel: +1-215-328-4300 www.liquent.com

Liquent regulatory solutions provide software and related regulatory and
clinical services for the life sciences industry. These solutions and
services help ensure clients meet the strict standards of regulatory
authorities across the world helping them achieve quality, accuracy, and data
integrity to deliver regulatory reports and submissions reliably and on time.

As a result, global life sciences companies, small tier to large tier,
rely on Liquent regulatory solutions to provide the technology and services
to compress the regulatory submissions and approval process, improving speed
to market, cost control, and productivity, all of which contribute to
ensuring patients' and physicians' timely access to new drugs. Over the last
decade, thousands of regulatory submissions have been produced using Liquent
world-class products and expert services. For more information please visit,
www.liquent.com.

About Marlin Equity Partners

Marlin Equity Partners is a Los Angeles, California-based private
investment firm with over US$1 billion of capital under management. The firm
is focused on providing corporate parents, shareholders and other
stakeholders with tailored solutions that meet their business and liquidity
needs in special situations. Marlin invests in businesses across multiple
industries that are in the process of undergoing varying degrees of
operational, financial or market-driven change where its capital base,
industry relationships and extensive network of operational resources
significantly strengthens a company's outlook and enhances value. Since its
inception, Marlin, through its group of funds and related companies, has
successfully completed over 30 acquisitions. For more information, please
visit www.marlinequity.com.

    Contact: Rick Riegel
             Chief Executive Officer
             +1-215-328-4302

Rick Riegel, Chief Executive Officer of Liquent, +1-215-328-4302